Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD

Journal of the American Society of Nephrology

Volumn 23, Issue 9, 2012, Pages 1551-1559

  Chan, Kevin E ^a,b   Warren, H Shaw ^b   Thadhani, Ravi I ^b   Steele, David J R ^b   Hymes, Jeffrey L ^a   Maddux, Franklin W ^a   Hakim, Raymond M ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFAZOLIN; CREATININE; HEMOGLOBIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BLOOD CULTURE; CHRONIC PATIENT; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; FEMALE; HAZARD RATIO; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; STAPHYLOCOCCAL BACTEREMIA;

EID: 84865970452     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012010050     Document Type: Article

References (32)

1. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Tolson J, Henderson T, Martone WJ; National Nosocomial Infections Surveillance System: Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 91: 86S-89S, 1991
2. Steinberg JP, Clark CC, Hackman BO: Nosocomial and communityacquired Staphylococcus aureus bacteremias from 1980 to 1993: Impact of intravascular devices and methicillin resistance. Clin Infect Dis 23: 255-259, 1996 (Pubitemid 126782779)
3. Frimodt-Møller N, Espersen F, Skinhøj P, Rosdahl VT: Epidemiology of Staphylococcus aureus bacteremia in Denmark from1957 to 1990. Clin Microbiol Infect 3: 297-305, 1997 (Pubitemid 27326118)
4. Lyytikäinen O, Ruotsalainen E, Järvinen A, Valtonen V, Ruutu P: Trends and outcome of nosocomial and community-acquired bloodstream infections due to Staphylococcus aureus in Finland, 1995-2001. Eur J Clin Microbiol Infect Dis 24: 399-404, 2005 (Pubitemid 40933914)
5. Skinner D, Keefer CS: Significance of bacteremia caused by Staphylococcus aureus: A study of one hundred and twenty-two cases and a review of the literature concerned with experimental infection in animals. Arch Intern Med 68: 851-875, 1941
6. Lowy FD: Staphylococcus aureus infections. N Engl J Med 339: 520-532, 1998
7. Mylotte JM, Tayara A: Staphylococcus aureus bacteremia: Predictors of 30-day mortality in a large cohort. Clin Infect Dis 31: 1170-1174, 2000 (Pubitemid 32295446)
8. Shurland S, Zhan M, Bradham DD, Roghmann MC: Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 28: 273-279, 2007 (Pubitemid 46480725)
9. Vandecasteele SJ, Boelaert JR, De Vriese AS: Staphylococcus aureus infections in hemodialysis: What a nephrologist should know. Clin J Am Soc Nephrol 4: 1388-1400, 2009
10. Chang FY, Peacock JE Jr, Musher DM, Triplett P, MacDonald BB, Mylotte JM, O'Donnell A, Wagener MM, Yu VL: Staphylococcus aureus bacteremia: Recurrence and the impact of antibiotic treatment in a prospectivemulticenter study.Medicine (Baltimore) 82: 333-339, 2003 (Pubitemid 37229468)
11. Fowler VG Jr, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, Cheng AC, Dudley T, Oddone EZ: Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 163: 2066-2072, 2003 (Pubitemid 37151249)
12. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C: Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 64: 95-100, 1993 (Pubitemid 23117176)
13. González C, Rubio M, Romero-Vivas J, González M, Picazo JJ: Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 29: 1171-1177, 1999 (Pubitemid 30265635)
14. Fowler VG Jr, Kong LK, Corey GR, Gottlieb GS, McClelland RS, Sexton DJ, Gesty-Palmer D, Harrell LJ: Recurrent Staphylococcus aureus bacteremia: Pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 179: 1157-1161, 1999 (Pubitemid 29196496)
15. Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller LB, Corey GR, Fowler VG Jr: Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 44: 190-196, 2007 (Pubitemid 46079979)
16. Levine DP: Vancomycin: A history. Clin Infect Dis 42[Suppl 1]: S5-S12, 2006
17. Hartstein AI, Mulligan ME, Morthland VH, Kwok RY: Recurrent Staphylococcus aureus bacteremia. J ClinMicrobiol 30: 670-674, 1992
18. Karchmer AW: Staphylococcus aureus and vancomycin: The sequel. Ann Intern Med 115: 739-741, 1991
19. Levine DP, Fromm BS, Reddy BR: Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115: 674-680, 1991
20. Mortara LA, Bayer AS: Staphylococcus aureus bacteremia and endocarditis. New diagnostic and therapeutic concepts. Infect Dis Clin North Am 7: 53-68, 1993 (Pubitemid 23103232)
21. Small PM, Chambers HF: Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34: 1227-1231, 1990 (Pubitemid 20177385)
22. Stevens DL: The role of vancomycin in the treatment paradigm. Clin Infect Dis 42[Suppl 1]: S51-S57, 2006
23. Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ: Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 17: 990-997, 1997 (Pubitemid 27415102)
24. Centers for Disease Control and Prevention (CDC): Invasivemethicillinresistant Staphylococcus aureus infections among dialysis patients-United States, 2005. MMWR Morb Mortal Wkly Rep 56: 197-199, 2007
25. Vandecasteele SJ, De Vriese AS: Recent changes in vancomycin use in renal failure. Kidney Int 77: 760-764, 2010
26. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82-98, 2009
27. Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, Pasko DA, Smoyer WE: Antimicrobial agents. In: Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th Ed., American College of Physicians, Philadelphia, PA, 2007, pp 52-68
28. Sowinski KM, Mueller BA, Grabe DW, Manley HJ, Frye RF, Bailie GR, Marx MA: Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis 37: 766-776, 2001 (Pubitemid 32268038)
29. Ahern JW, Possidente CJ, Hood V, Alston WK: Cefazolin dosing protocol for patients receiving long-term hemodialysis. Am J Health Syst Pharm 60: 178-181, 2003 (Pubitemid 36427049)
30. Marx MA, Frye RF, Matzke GR, Golper TA: Cefazolin as empiric therapy in hemodialysis-related infections: Efficacy and blood concentrations. Am J Kidney Dis 32: 410-414, 1998 (Pubitemid 28411213)
31. Conditions for Coverage (CFC): 2009. Available at: http://www. networkofnewengland.org/CFC.htm. Accessed July 25, 2011
32. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC Definitions for Nosocomial Infections. APIC Infection Control and Applied Epidemiology: Principles and Practice. A1-A20, St. Louis,MO, Mosby, 1996